Cardiovascular Drugs

The three start-ups profiled in this group of companies are employing a variety of scientific platforms and business models to develop treatments for cardiovascular disease. Excigen (gene therapy to treat arrhythmias) and Endogeny (cell therapy to repair damaged heart tissue) are using cutting-edge approaches to discover and develop novel therapeutics, while QuatRx is an in-licensing company with a lipid -regulating compound that may enter the clinic next year. What all three have in common is a focus on products and an intent to outlicense their products for late-stage development and commercialization.

Cardiovascular disease (CVD) exacts a staggering human and economic toll each year. It claims more American lives than the next five leading causes of death combined and, with the exception of the influenza-ridden year of 1918, has been the number one killer in the US since 1900. Nearly 40% of all deaths in the US result from CVD. And with an aging baby boom population (over a third of all Americans between the ages of 45 and 54 have CVD), an increasingly sedentary lifestyle, and growing rates of obesity, those numbers are unlikely to go down any time soon.

It's a health problem so prevalent that two University of London scientists recently announced that they are working on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

Lupin’s Cimzia Biosimilar Candidate Reflects Strategy To Separate Wheat From Chaff

 
• By 

Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers

Finance Watch: Two New Venture Capital Funds Provide $600m For Biopharma

 
• By 

Private Company Edition: Catalio raised more than $400m for its fourth health care-focused VC fund, while AN Venture Partners raised $200m for Japan and beyond. In VC financings, among a dearth of mega rounds, Neuron23’s $96.5m series D is the largest round in recent weeks.

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.